attenuated virus

These attenuated viruses produce little or no illness in most people.

To make the vaccine, the attenuated virus is grown in chicken eggs as before.

In 1969 a live attenuated virus vaccine was licensed.

An attenuated virus, like that used in vaccines against chickenpox, may prove more effective.

In the early 1970's, Japanese scientists developed a chicken pox vaccine using live, attenuated viruses.

Dr. Hextall identifies a potential vaccine, using an attenuated virus.

It is a mixture of live attenuated viruses of the three diseases, administered via injection.

Attenuated virus mutants represent a promising approach towards gamma-herpesvirus infection control.

But he and other experts said much more research was needed to be sure that such an attenuated virus vaccine was both safe and effective.

"But it uses a live, attenuated virus.

The Sabin vaccine, though easier to use and highly effective, was made from live attenuated viruses, some of which apparently retained their infectious potential.

'Second, we need to create an appropriate viral vector, which as you know is essentially an attenuated virus.'

More important than any lack of efficacy is the very real risk that vaccines prepared from killed or attenuated virus particles may contain carcinogenic elements.

Since agglutination is rarely linked to infectivity, attenuated viruses can therefore be used in assays.

Additionally, since VLPs lack genetic material, they provide a safer alternative to attenuated viruses.

The more advanced consist of tetravalent mixtures of live attenuated viruses representing each serotype.

There are two types of vaccines: one containing inactivated hepatitis A virus, and another containing a live but attenuated virus.

Two live attenuated virus vaccines, RA 27/3 and Cendehill strains, were effective in the prevention of adult disease.

Attenuated virus vaccines, like the Sabin oral polio vaccine, are similar to the disease-causing versions except that they have lost the genetic capacity for virulence.

Such research ultimately could lead to the detection of an attenuated virus that could be used in the production of an AIDS vaccine.

On very rare occasions (about 1 case per 750,000 vaccine recipients) the attenuated virus in OPV reverts into a form that can paralyze.

Therefore, live attenuated viruses require three immunizations over an extended dosing schedule of 12 months to elicit balanced neutralizing antibody responses to all 4 serotypes.

When animals inoculated with this attenuated virus were challenged again with virulent SIV, they were protected from the otherwise lethal infection.

Their Synthetic Attenuated Virus Engineering (SAVE) approach has been validated in flu and experiments with other viruses are ongoing.

Lastly, proven vaccine approaches from the past have either failed (whole killed virus and subunit vaccines) or faced seemingly insurmountable regulatory hurdles (live attenuated virus vaccine).